Cargando…
A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive modulator (HEI3090) of the purinergic P2RX7 receptor that potentiates αPD-1 treat...
Autores principales: | Douguet, Laetitia, Janho dit Hreich, Serena, Benzaquen, Jonathan, Seguin, Laetitia, Juhel, Thierry, Dezitter, Xavier, Duranton, Christophe, Ryffel, Bernhard, Kanellopoulos, Jean, Delarasse, Cecile, Renault, Nicolas, Furman, Christophe, Homerin, Germain, Féral, Chloé, Cherfils-Vicini, Julien, Millet, Régis, Adriouch, Sahil, Ghinet, Alina, Hofman, Paul, Vouret-Craviari, Valérie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843983/ https://www.ncbi.nlm.nih.gov/pubmed/33510147 http://dx.doi.org/10.1038/s41467-021-20912-2 |
Ejemplares similares
-
Alternative splicing of P2RX7 pre-messenger RNA in health and diseases: Myth or reality?
por: Benzaquen, Jonathan, et al.
Publicado: (2019) -
Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
por: Janho dit Hreich, Serena, et al.
Publicado: (2023) -
The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
por: Janho dit Hreich, Serena, et al.
Publicado: (2023) -
The Purinergic Landscape of Non-Small Cell Lung Cancer
por: Janho dit Hreich, Serena, et al.
Publicado: (2022) -
P2RX7B is a new theranostic marker for lung adenocarcinoma patients
por: Benzaquen, Jonathan, et al.
Publicado: (2020)